Suchergebnisse - "Buti, Maria"

PubPharm (22)

1

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a : Week 120 Analysis

enthalten in: Digestive diseases and sciences | 2018

von Ahn, S. | Marcellin, P. | Ma, X. | +19

ErratumIn: Dig Dis Sci. 2018 Oct 15;:. - PMID 30324553

2

Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B

enthalten in: Annals of hepatology | 2017

von Oyagüez, I. | Buti, M. | Brosa, M. | +2

3

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

enthalten in: PloS one | 2017

von Asselah, T. | Moreno, C. | Sarrazin, C. | +12

4

Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C : Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis

enthalten in: Gastroenterologia y hepatologia | 2016

von Buti, M. | Domínguez-Hernández, R. | Oyagüez, I. | +1

5

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

enthalten in: Gastroenterology | 2016

von Marcellin, P. | Ahn, S. | Ma, X. | +28

CommentIn: Gastroenterology. 2016 Jan;150(1):32-4. - PMID 26615120

6

Lead-in period and week 8 as predictive tools for response to boceprevir therapy : a retrospective study of Spanish real clinical practice

enthalten in: Gastroenterologia y hepatologia | 2015

von Crespo, J. | Berenguer, M. | Pérez, F. | +7

7

Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis : SVRw12 analysis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2015

von Calleja, J. | Pascasio, J. | Ruiz-Antorán, B. | +73

8

Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2014

von Buti, M. | Gros, B. | Oyagüez, I. | +4

9

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2) : a randomised, double-blind, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2014

von Manns, M. | Marcellin, P. | Poordad, F. | +13

ErratumIn: Lancet. 2016 Apr 30;387(10030):1816. - PMID 27203505

10

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C

enthalten in: Annals of hepatology | 2014

von Ampuero, J. | Del Campo, J. | Rojas, L. | +12